Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02604511
Recruitment Status : Completed
First Posted : November 13, 2015
Results First Posted : January 12, 2022
Last Update Posted : December 7, 2022
Pharmacyclics LLC.
Information provided by (Responsible Party):
Steven Treon, MD, PhD, Dana-Farber Cancer Institute

Brief Summary:
This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

Condition or disease Intervention/treatment Phase
Waldenstrom's Macroglobulinemia Drug: Ibrutinib Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has approved ibrutinib as a form of treatment for the patient specific disease.

Ibrutinib has been under investigation in research studies in participants with recurrent B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and prolymphocytic leukemia, and WM. In a study of ibrutinib in relapsed/refractory WM patients, response rates were high and the treatment was well tolerated.

The prior studies suggest that ibrutinib may be a useful treatment strategy for untreated WM patients. This study will test the safety and efficacy of ibrutinib as an option for untreated WM patients. The study will also conduct genomic sequencing of malignant WM cells before the start of treatment, and 6, 12, 24, 36 and 48 months afterwards. Genomic sequencing is the analysis of the entire DNA structure from tumor and normal cells. The purpose of this sequencing is to study which genetic changes effect how ibrutinib works. The results of these studies could also help in better understanding the course of WM disease, and be applicable to the development of other effective drug treatments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Actual Study Start Date : January 2016
Actual Primary Completion Date : November 1, 2022
Actual Study Completion Date : November 1, 2022

Arm Intervention/treatment
Experimental: Ibrutinib
This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
Drug: Ibrutinib
Other Names:
  • Imbruvica
  • PCI-32765

Primary Outcome Measures :
  1. Major Response Rate [ Time Frame: 4 years ]
    To asses the percentage of participants with a Partial Response (PR) (50% reduction or more in serum IgM) or better.

  2. Best Overall Response Rate [ Time Frame: 4 years ]
    To asses the percentage of participants with an Minor Response (MR) (25% reduction or more in serum IgM) or better.

Secondary Outcome Measures :
  1. Duration of Response [ Time Frame: 6 years ]
    The amount of time between attainment of at least a minor response and disease progression.

Other Outcome Measures:
  1. Time to Response [ Time Frame: 4 years ]
    The amount of time between starting treatment and attaining at least a minor response to therapy

  2. Progression Free Survival [ Time Frame: 6 years ]
    The number of participants who have not experienced disease progression 6 years after therapy initiation

  3. Overall Survival [ Time Frame: 6 years ]
    The number of participants who are still living 6 years after initiation of ibrutinib

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Kyle et al, 2003).
  • Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of ≥ 2 times the upper limit of normal is required.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix A.).
  • Participants must have normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1,000/μL
    • Platelets ≥ 50,000/μL
    • Hemoglobin ≥ 8 g/dL
    • Total bilirubin ≤ 2.0. mg/dL or < 2.5 mg/dL if attributable to hepatic infiltration by neoplastic disease or Gilbert's syndrome.
    • Aspartate aminotransferase (AST or SGOT) and Alanine aminotransferase (ALT or SGPT) ≤ 2.5 X institutional upper limit of normal
    • Estimated Creatinine Clearance ≥30ml/min
  • Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.
  • Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

  • Prior systemic therapy for WM
  • Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent the participant from signing the informed consent form.
  • Concurrent use of any other anti-cancer treatments or any other investigational agents.
  • Concomitant use of warfarin or other Vitamin K antagonists.
  • Concomitant treatment with strong CYP3A4/5 inhibitor.
  • Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion could interfere with the absorption or metabolism of ibrutinib.
  • Known Central nervous system (CNS) lymphoma.
  • Concomitant use of medication known to cause QT prolongation.
  • Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within 6 months of screening.
  • Malabsorption, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  • Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
  • Lactating or pregnant women.
  • Inability to swallow capsules.
  • History of non-compliance to medical regimens.
  • Unwilling or unable to comply with the protocol.
  • Major surgery within 4 weeks of first dose of study drug.
  • No active infections requiring systemic therapy.
  • Known bleeding disorders with the exception of acquired Von Willebrand Disorder suspected on the basis of WM.
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02604511

Layout table for location information
United States, Massachusetts
Massacusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Dana-Farber Cancer Institute
Pharmacyclics LLC.
Layout table for investigator information
Principal Investigator: Steven P Treon, MD, PhD Dana-Farber Cancer Institute
  Study Documents (Full-Text)

Documents provided by Steven Treon, MD, PhD, Dana-Farber Cancer Institute:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Steven Treon, MD, PhD, Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute Identifier: NCT02604511    
Other Study ID Numbers: 15-359
First Posted: November 13, 2015    Key Record Dates
Results First Posted: January 12, 2022
Last Update Posted: December 7, 2022
Last Verified: December 2022
Keywords provided by Steven Treon, MD, PhD, Dana-Farber Cancer Institute:
Waldenstrom's Macroglobulinemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Waldenstrom Macroglobulinemia
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases